Monoclonal antibodies and remdesivir treated Bundibugyo virus case

Researchers published a case study in Nature Medicine detailing the successful treatment of a Bundibugyo virus patient in Uganda using a combination of monoclonal antibodies (mAb114) and remdesivir. The patient, a 16-year-old boy, fully recovered from the severe viral hemorrhagic fever after 21 days of therapy, showing how these antivirals can support the body's immune response against aggressive pathogens. This is a rare, life-threatening Ebola-like virus with limited treatment options.